4
Changes in Ownership
CRISPR Therapeutics AG Filed Acc 0000950170-24-016574
Chief Executive Officer sold 20,000 shares at an average $80.36 ($1,607,177)
- Chief Executive Officer acquired 20,000 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Kulkarni Samarth Chief Executive Officer | 2024-02-15 | Option exercise 10b5-1 | +20,000 | $19.12 | $382,400 | 207,377 | D |
| Kulkarni Samarth Chief Executive Officer | 2024-02-15 | Sale 10b5-1 | −12,949 | $79.94 | $1,035,090 | 194,428 | D |
| Kulkarni Samarth Chief Executive Officer | 2024-02-15 | Sale 10b5-1 | −5,951 | $81.04 | $482,257 | 188,477 | D |
| Kulkarni Samarth Chief Executive Officer | 2024-02-15 | Sale 10b5-1 | −1,100 | $81.66 | $89,831 | 187,377 | D |
| Derivatives | |||||||
| Kulkarni Samarth Chief Executive Officer | 2024-02-15 | Option exercise · Stock Option (Right to Buy) 10b5-1 | −20,000 | 39,582 | D | ||
| Open-market sales · 20,000 sh · avg $80.36 · $1,607,177 | |||||||
Loading xslF345X05/ownership.xml…